Evidence map›Paper›PMID 33574979›Full record

ArticleOxidative medicine and cellular longevity2021

GSTM1 Modulates Expression of Endothelial Adhesion Molecules in Uremic Milieu.

Djurdja Jerotic, Sonja Suvakov, Marija Matic, Abdelrahim Alqudah, David J Grieve, Marija Pljesa-Ercegovac, Ana Savic-Radojevic, Tatjana Damjanovic, Nada Dimkovic, Lana McClements and 1 more

Open access · hybridAbstract read
In one paragraph

Article in Oxidative medicine and cellular longevity, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
0.7field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it, 12 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Leukocyte-endothelial interaction in CKD.Clinical kidney journal · 2023
    Review
  8. Article
  9. Hypertension (Dallas, Tex. : 1979) · 2021
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 6 institutions in 5 countries.

Djurdja JeroticInstitute of Medical and Clinical Biochemistry, Faculty of Medicine, University of Belgrade, 11000 Belgrade, Serbia.ORCID https://orcid.org/0000-0002-1664-6557
Sonja SuvakovInstitute of Medical and Clinical Biochemistry, Faculty of Medicine, University of Belgrade, 11000 Belgrade, Serbia.
Marija MaticInstitute of Medical and Clinical Biochemistry, Faculty of Medicine, University of Belgrade, 11000 Belgrade, Serbia.
Abdelrahim AlqudahDepartment of Clinical Pharmacy and Pharmacy Practice, Faculty of Pharmaceutical Sciences, The Hashemite University, P.O. Box 330127 Zarqa 13133, Jordan.
David J GrieveThe Wellcome-Wolfson Institute for Experimental Medicine, School of Medicine, Dentistry and Biomedical Sciences, Queen's University Belfast, Belfast, UK.
Marija Pljesa-ErcegovacInstitute of Medical and Clinical Biochemistry, Faculty of Medicine, University of Belgrade, 11000 Belgrade, Serbia.
Ana Savic-RadojevicInstitute of Medical and Clinical Biochemistry, Faculty of Medicine, University of Belgrade, 11000 Belgrade, Serbia.
Tatjana DamjanovicClinical Department for Renal Diseases, Zvezdara University Medical Center, 11000 Belgrade, Serbia.
Nada DimkovicFaculty of Medicine, University of Belgrade, 11000 Belgrade, Serbia.
Lana McClementsThe Wellcome-Wolfson Institute for Experimental Medicine, School of Medicine, Dentistry and Biomedical Sciences, Queen's University Belfast, Belfast, UK.ORCID https://orcid.org/0000-0002-4911-1014
Tatjana SimicInstitute of Medical and Clinical Biochemistry, Faculty of Medicine, University of Belgrade, 11000 Belgrade, Serbia.ORCID https://orcid.org/0000-0001-8683-5129
University of Belgrade · RSQueen's University Belfast · GBKliničko Bolnički Centar Zvezdara · RSMayo Clinic · USSerbian Academy of Sciences and Arts · RSUniversity of Technology Sydney · AU

Funding

British Heart Foundation FS/14/35/30813British Heart Foundation PG/14/78/31099British Heart Foundation PG/19/61/34586
6 · The paper itself

Abstract

Deletion polymorphism of glutathione S-transferase M1 (GSTM1), a phase II detoxification and antioxidant enzyme, increases susceptibility to end-stage renal disease (ESRD) as well as the development of cardiovascular diseases (CVD) among ESRD patients and leads to their shorter cardiovascular survival. The mechanisms by which GSTM1 downregulation contributes to oxidative stress and inflammation in endothelial cells in uremic conditions have not been investigated so far. Therefore, the aim of the present study was to elucidate the effects of GSTM1 knockdown on oxidative stress and expression of a panel of inflammatory markers in human umbilical vein endothelial cells (HUVECs) exposed to uremic serum. Additionally, we aimed to discern whether

Indexed as

BiomarkersCytokinesGene DeletionGlutathione PeroxidaseGlutathione TransferaseHumansHuman Umbilical Vein Endothelial CellsIntercellular Adhesion Molecule-1Kidney Failure, ChronicMalondialdehydeOxidative StressProteomeReactive Oxygen SpeciesSuperoxide DismutaseUremiaVascular Cell Adhesion Molecule-1BiomarkersCytokinesGlutathione PeroxidaseGlutathione TransferaseIntercellular Adhesion Molecule-1MalondialdehydeProteomeReactive Oxygen SpeciesSuperoxide DismutaseVascular Cell Adhesion Molecule-1

Identifiers

PMID33574979
PMCPMC7860968
OpenAlexW3122219752

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.